About the deal
Founded in 2002, CTRS (Cell Therapies Research & Services laboratory) is a French pharmaceutical company that develops and markets treatments for patients with strong unmet medical needs, with a particular focus on orphan diseases. The company can count on approx. 20 employees and generated €15.7 M in 2019.
Mérieux Equity Partners is a global investment platform specialized in the healthcare & nutrition sector, working alongside entrepreneurs and companies with ambitious growth plan, offering them privileged access to sector-expertise and industrial network.
Merieux Equity Partners invested in laboratoires CTRS alongside the management team, via its Merieux Participations 3 vehicle.
What we did
Capitalmind has advised CTRS shareholders all along the OBO process: designing the transaction strategy, building a relevant qualified list of PE funds and organization of a competitive process, management of the debt financing process, marketing of the deal, execution and negotiation up to closing.